[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"corona-virus-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:corona-virus-infection":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,41,67,103,135,161,183],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100406989","understanding-immunity-to-the-flu-vaccine-in-covid-19-patients-100406989",false,"NCT04579588","Understanding Immunity to the Flu Vaccine in COVID-19 Patients","Inclusion Criteria:\n\n* Age 9 through 64 years\n* Diagnosed with COVID-19 at least 2 months prior enrollment\n* Patients with or without obesity, diabetes, chronic fatigue and\u002For long term COVID-19 symptoms\n* Patients without COVID-19 diagnosis for controls\n\nExclusion Criteria:\n\n* Received the influenza vaccine less than 4 months ago\n* Pregnant or lactating\n* Patients with special risks attendant to venipuncture\n* Use of immunomodulatory medications that may impact vaccine immune response per clinician's judgment\n* Contraindication to the flu vaccine\n* Immunodeficiency or autoimmune disease that may impact vaccine immune responses per clinician's judgement",true,"ALL","9 Years","64 Years",{"count":20,"type":21},230,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to measure immunity to the flu vaccine over time in patients who have had COVID-19 and may have other medical conditions including obesity, type 2 diabetes, chronic fatigue, or long-term COVID-19 symptoms. Adults and children (age 9 to 64) who had been diagnosed with COVID-19 as well as controls without COVID-19 will be invited to participate in this study.",[25,26,27],"Corona Virus Infection","Flu Vaccine","Immunity","RECRUITING","2026-03-16",{"date":31,"type":32},"2026-03-18","ACTUAL",{"date":34,"type":32},"2020-10-29",{"date":36,"type":21},"2028-04",{"name":38,"class":39},"Stanford University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":52,"conditions":53,"keywords":56,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":40},"100396902","determinants-of-sars-severe-acute-respiratory-syndrome-cov2-covid-19-persistence-after-convalescence-100396902","NCT04448145","Determinants of SARS (Severe Acute Respiratory Syndrome)-COV2 (COVID-19) Persistence After Convalescence","Characterizing SARS-CoV-2 Persistence in Host Reservoirs, Post-viral Sequelae, and Associations With Host and Viral Determinants in a Cohort of Convalescent COVID-19 Cases","C-PIC","Inclusion Criteria:\n\n* Laboratory confirmed SARS-CoV-2 using currently available laboratory testing techniques (e.g.,RT-PCR, Immunoglobulin M (IgM) \u002FIgG) or clinical history compatible with a COVID-19 like illness(fever, cough, shortness of breath).\n* Negative participants with no known prior COVID-19 diagnosis or COVID vaccine\n* At least 7 years of age\n* Participants are eligible to provide semen and breast milk samples if they are 18 years of age or older\n\nExclusion Criteria:\n\n* Age \\\u003C7\n* Intercurrent conditions that in the opinion of the investigator would confound the findings of the study.","7 Years",{"count":51,"type":21},800,"The 2019-2020 COVID-19 pandemic is the largest outbreak in recent history. It is not known how long after someone gets sick with COVID-19 and recovers that they can still infect other people. It is also not known how quickly people make antibodies against the virus, which help clear infection from the body. The investigators will enroll 300 people who had COVID-19 based on lab testing or confirmed exposure to participate. An additional 25 participants who have never tested positive for COVID and have not had the vaccine will be enrolled as negative controls. Participants will complete a survey at enrollment. The investigators will also collect blood, nose swab, saliva, stool, semen, and breast milk to test for the virus. The investigators will ask participants to complete a survey and give specimens up to 12 times over 24 months. This information will be used to study how long the virus can live in different parts of the body, antibody development, and post-infectious complications. The investigators hope that this information will allow medical and public health providers to make recommendations to better care for patients in the convalescent phase of COVID-19 infection.",[54,25,55],"COVID-19","SARS-CoV 2",[57],"Novel Coronavirus","2025-11-03",{"date":60,"type":32},"2025-11-05",{"date":62,"type":32},"2020-03-26",{"date":64,"type":21},"2026-09",{"name":66,"class":39},"Columbia University",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":15,"sex":16,"minAge":75,"maxAge":4,"enrollmentInfo":76,"targetDuration":78,"studyType":22,"phases":4,"briefSummary":79,"conditions":80,"keywords":85,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100416676","kidney-injury-in-times-of-covid-19-kidcov-100416676","NCT04705766","KIDney Injury in Times of COVID-19 (KIDCOV)","The KIDCOV Study: ASSESSMENT of SARS-CoV-2 Without HOSPITALIZATION as a RISK FACTOR for ACUTE KIDNEY INJURY","KIDCOV","Inclusion Criteria:\n\n* Result of PCR-based COVID-19 test conducted in the past 4 weeks posted in EMR of participating AMC\n* Age 18 years or older at enrollment\n* Race\u002Fethnicity, sex, age, and phone and\u002For home\u002Femail address provided\n\nExclusion Criteria:\n\n* Failure of a candidate participant to give written informed consent to comply with the study protocol\n* Hospitalization up to 4 weeks after SARS-CoV-2 test\n* History of kidney transplant\n* History of dialysis","18 Years",{"count":77,"type":21},2000,"1 Year","There is an unmet need to evaluate the impact of sub-clinical\u002Fmild COVID19 disease in the outpatient setting on prevalent and incident renal injury, as this data is currently unavailable. To capture the diversity of race\u002Fethnic risk and COVID19 related municipal shelter-in-place guidance, the investigators will enroll COVID19-negative and COVID19-positive samples balanced by race\u002Fethnicity from 3 different states, California, Michigan, and Illinois. Study endpoints will be assayed from urine samples mailed to the study team at 2, 6, and 12 months after their date of PCR test, with no requirement for these individuals to leave their homes to participate.",[81,82,25,83,84],"SARS-CoV Infection","Covid19","Acute Kidney Injury","Kidney Injury",[86,83,54,87,88,89,90,91,92,84],"SARS-CoV-2","Coronaviurs","COVID-19 Infection","SARS-CoV-2 infection","Coronavirus infection","COVID-19 and Acute Kidney Injury","SARS-CoV-2 & Kidney Injury Risk Factors","2025-07-24",{"date":95,"type":32},"2025-07-28",{"date":97,"type":32},"2021-03-01",{"date":99,"type":21},"2027-03",{"name":101,"class":39},"University of California, San Francisco",3,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":15,"sex":16,"minAge":75,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":112,"conditions":113,"keywords":122,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":40},"100390125","a-study-to-explore-the-role-of-gut-flora-in-covid-19-infection-100390125","NCT04359836","A Study to Explore the Role of Gut Flora in COVID-19 Infection","A Non-Interventional Pilot Study to Explore the Role of Gut Flora in COVID-19 Infection","Inclusion Criteria:\n\n1. Signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study\n2. Male or female of 18 years of age or older\n3. Diagnosis of COVID-19 infection by RT- PCR within 1 week of Screening\n\nExclusion Criteria:\n\n1. Refusal to sign informed consent form\n2. History of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy.\n3. Postoperative stoma, ostomy, or ileoanal pouch\n4. Treatment with total parenteral nutrition",{"count":111,"type":21},250,"This study seeks to determine whether the virus which causes COVID-19, SARS-CoV-2, is shed in the stools of patients who are infected.",[114,115,116,54,25,117,118,119,120,121],"Gut Microbiome","Gastrointestinal Microbiome","COVID","Coronavirus","Coronaviridae Infections","Coronavirus 19","Coronavirus-19","COVID 19",[123,117,124,125,116,54],"Microbiome","Corona Virus","19","2025-06-02",{"date":128,"type":32},"2025-06-05",{"date":130,"type":32},"2020-04-16",{"date":132,"type":21},"2027-07-31",{"name":134,"class":39},"ProgenaBiome",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":75,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":145,"phases":146,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":4},"100440592","phase-2-clinical-study-for-subjects-with-covid-19-using-allogeneic-adipose-tissue-derived-mesenchymal-stem-cells-100440592","NCT05017298","Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells","Clinical Study for Subjects With Coronavirus 2019 (COVID-19) Using Multiple Dose Intravenous Infusions of Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs)","AdMSCs","Inclusion Criteria:\n\n* Age above 18 years.\n* Male and female\n* Must understand and voluntarily sign an Informed Consent for study participation obtained prior to undergoing any study-specific procedures\n* Diagnosed as COVID-19 based upon SARS-CoV-2 RT-PCR test positive\n* Clinical diagnosis meets severe and\u002For critical parameters\n* Male participants must be willing to ensure their partners do not become pregnant either by practicing abstinence or the use of condoms during sexual activity\n\nExclusion Criteria:\n\n* Participation in another clinical study (with use of another Investigational Medical Product) within 3 months prior to study treatment start\n* Unwillingness or inability to comply with study procedures\n* Patients with serious basic diseases that affect survival, including blood diseases, cachexia, active bleeding, severe malnutrition, etc.\n* Clinically active malignant disease\n* Subjects who are receiving ECMO and CRRT currently\n* History of known pulmonary embolism or known secondary anti-phospholipid syndrome\n* Known or suspected hypersensitivity to any components used to culture the AdMSCs, e.g. BSA and sulfur containing products (e.g., DMSO)\n* Known or suspected allergic to diphenhydramine.\n* Major trauma or surgery within 14 days of study treatment start\n* Mental condition rendering the subject (or the subject's legally acceptable representative\\[s\\]) unable to understand the nature, scope and possible consequences of the study\n* Alcohol, drug, or medication abuse within one year prior to study treatment start\n* Any condition that, in the Investigator's opinion, is likely to interfere with evaluation of the AdMSC therapy or satisfactory conduct of the study\n* Irreversible severe end organ failure, such as heart failure\u002Fattack, stroke, liver and renal failure due to other disease conditions\n* Patients or family history with hypercoagulable status, such as protein C\u002Fprotein S deficiency, factor V Leiden, prothrombin gene mutation, dysfibrinogenemia, etc.\n* History of long-term use of immunosuppressive agents\n* Organ transplants in the past 6 months\n* Pregnant, breastfeeding, or desire to become pregnant or unwilling to practice birth control during participation in the study duration, unless surgically sterilized or postmenopausal during the study.\n* Patients with previous pulmonary obstructive pneumonia, severe pulmonary interstitial fibrosis, alveolar proteinosis, allergic alveolitis, and other known viral pneumonia or bacterial pneumonia before COVID-19 infection. The pulmonary imaging revealed the interstitial damage of lungs before the COVID-19 confirmed.\n* QT interval shows greater than 450 ms in males and 470 ms in females in the medical histories or during screen EKG test.\n* Subjects are not medically unstable at time of infusion including but not limiting unstable hypertension, pulse, oximetry, etc.",{"count":144,"type":21},30,"INTERVENTIONAL",[147],"PHASE2","This is an interventional new drug clinical trial for a Phase 2 randomized, double-blind, and placebo control study using intravenous injection of allogeneic adipose stem cells (Celltex AdMSCs) for subjects with severe COVID-19.",[25,82],"NOT_YET_RECRUITING","2024-02-05",{"date":153,"type":32},"2024-02-07",{"date":155,"type":21},"2024-11-01",{"date":157,"type":21},"2026-11-15",{"name":159,"class":160},"Celltex Therapeutics Corporation","INDUSTRY",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":16,"minAge":75,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":168,"phases":4,"briefSummary":169,"conditions":170,"keywords":173,"overallStatus":177,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":181,"locationsCount":4},"100412964","expanded-access-to-zofin-for-patients-with-covid-19-100412964","NCT04657406","Expanded Access to Zofin for Patients With COVID-19","Expanded Access to Zofin for the Treatment of Patients With Mild to Moderate COVID-19 Due to SARS-Cov-2 for Outpatient and Inpatient Population","Inclusion Criteria:\n\n1. Provide written informed consent\n2. Subjects age \\> 18 years at the time of signing the Informed Consent Form.\n3. Male or Female\n4. Must have a clinical diagnosis of COVID-19 by the qualitative reverse-transcription polymerase chain reaction (RT-PCR), with at least one of mild or moderate COVID-19 clinical symptoms which are defined below in #5\n5. Individuals with mild to moderately COVID-19 symptoms for outpatient and inpatient population.\n\n   The main symptoms of mild illness are:\n   * low grade fever \\\u003C38°C (37.5 to 37.9)\n   * a dry cough\n   * tiredness\n   * feeling slightly breathless\n   * muscle pain\n   * headache\n   * sore throat\n   * diarrhea\n\n   The main symptoms of moderate illness are:\n\n   In addition to the symptoms patients may get with a mild illness, they may also experience:\n   * fever ≥38°\n   * a dry and more persistent cough several times an hour\n   * tiredness and a need to stay in bed\n   * feeling breathless when doing moderate exercise (such as walking upstairs)\n   * muscle pain and aches and need to stay in bed\n   * headache particularly if you are feeling hot\n   * sore throat, soreness from coughing, but no pain\n   * diarrhea\n   * a dry mouth\n6. Adequate venous access\n7. For Women of Child-Bearing Potential (WOCBP) only, willingness to use FDA-recommended birth control until 6 months post treatment. The FDA-approved and cleared methods for birth control are listed below:\n\n   * Permanent Sterilization\n   * Long-Acting Reversible Contraceptives (LARC)\n   * Contraceptive Injection\n   * Short-Acting Hormonal Methods\n   * Barrier Methods\n   * Emergency Contraception\n\n   https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Ffree-publications-women\u002Fbirth-control\n8. Any male subject must agree to use contraceptives and not donate sperm during the study.\n9. Must agree to comply with all protocol requirements and be willing to complete all study visits\n\nExclusion Criteria:\n\n1. Patients who have moderate to severe respiratory distress syndrome due to COVID-19\n2. Be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods. Female subjects must undergo a blood pregnancy test at screening which will be within 72 hours of the IP infusion.\n3. Inability to perform any of the assessments required.\n4. Active listing (or expected future listing) for transplant of any organ.\n5. Be a solid organ transplant recipient. This does not include prior cell-based therapy (\\>12 months prior to enrollment), bone, skin, ligament, tendon or corneal grafting. Have a history of organ or cell transplant rejection.\n6. History of drug abuse (illegal \"street\" drugs except marijuana (If it is legal use in states where patient resides), or prescription medications not being used appropriately for a pre-existing medical condition or alcohol abuse (≥ 5 drinks\u002Fday for ˃ 3 months), or documented medical, occupational, or legal problems arising from the use of alcohol or drugs within the past 24 months\n7. Patients with untreated HIV infection. However, patients can be enrolled if have been treated for HIV and the test negative for HIV viral load but still test positive for antibodies.","EXPANDED_ACCESS","This expanded access protocol will provide access to the investigational product Zofin for patients in outpatient facilities infected with SARS-CoV-2 who have mild to moderate COVID-19, or who are judged by a healthcare provider to be at high risk of progression to moderate disease.",[82,25,171,172],"SARS (Severe Acute Respiratory Syndrome)","Acute Respiratory Distress Syndrome",[174,175,176],"Human","Exosomes","Human Amniotic Fluid","AVAILABLE","2023-03-21",{"date":180,"type":32},"2023-03-23",{"name":182,"class":160},"ZEO ScientifiX, Inc.",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":16,"minAge":75,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":145,"phases":192,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":205},"100391888","phase-3-novel-regimens-in-covid-19-treatment-100391888","NCT04382846","Novel Regimens in COVID-19 Treatment","Nitazoxanide in Treatment of COVID-19","Inclusion Criteria:\n\n* Patients with COVID-19 infection\n\nExclusion Criteria:\n\n* Allergy or contraindication to the drugs.",{"count":191,"type":21},160,[193],"PHASE3","Nitazoxanide has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.",[116,25],"2020-12-02",{"date":198,"type":32},"2020-12-04",{"date":200,"type":32},"2020-05-08",{"date":202,"type":21},"2030-12-01",{"name":204,"class":39},"Tanta University",2]